Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

NCT00092482 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

3882

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer
Genital Warts

Interventions

BIOLOGICAL: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years

Sponsor

Merck Sharp & Dohme LLC